Tivic receives two investigational new drug applications for entolimod™ for the treatment of acute radiation syndrome (ars) and advanced cancers

Fremont, calif.--(business wire)--tivic health® systems, inc. (nasdaq: tivc), a diversified immunotherapeutics company, today announced it has received, from statera biopharma, two investigational new drug applications (inds) for its lead candidate, entolimod™. the two inds cover the use of entolimod to treat acute radiation syndrome, including both hematopoietic (ars-h) and gastrointestinal (ars-gi) sub-syndromes, and the use of entolimod to treat advanced cancers, including as an anti-tumor a.
TIVC Ratings Summary
TIVC Quant Ranking